Products / Oncology and Oncohematology

Bemux

Bendamustine 25-100 mg

Bendamustine is indicated for the treatment of the chronic lymphocytic leukemia (CLL). It is also indicated to treat patients with indolent B-cell non-Hodking lymphoma.

Therapeutic Action

Antineoplastic

Presentation

25 mg — 1 lyophilized vial

Download Prospect

100 mg — 1 lyophilized vial

Download Prospect
Bemux Bendamustine 25-100 mg de Laboratorios Richmond

Legal Notice

Products which continue to have a valid patent protection at present are manufactured in line with the current laws of the Argentine Republic. Please, take into account that our products will only be shipped to countries where the substance and its use are not protected by patents.

Laboratorios Richmond S.A.C.I.F. Argentina © All rights reserved Terms of use Privacy policy